A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

Trial Details

NCT ID

NCT06783816

Phase

NA

Sponsor

Shanxi Bethune Hospital

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

• chimeric antigen receptor gene modified T cells

Locations (sample)

• Taiyuan, Shanxi, China|37.86944,112.56028

Key Eligibility Criteria

• I (or the authorized representative/legal guardian) agree and have signed an informed consent form, and am willing and capable of following the pla…
• Histopathological or flow cytometric diagnosis of CD19 and/or CD22, BCMA-positive hematological malignancies;
• ≥15 years old, ≤80 years old;
• If you meet one of the following three conditions, you can be included in the group:-Patients with recurrent or refractory hematologic malignancies…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.